Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.5 EUR
12.83 M EUR
100.20 M EUR
3.12 M
About PHARMANUTRA
Sector
CEO
Andrea Lacorte
Headquarters
Pisa
Website
Founded
2003
ISIN
IT0005274094
FIGI
BBG00H5FW2L0
Pharmanutra SpA develops nutraceutical products and medical devices. Its Sroscaloidal Iron intends to restore articular and movement ability in osteoarticular affections, consisting of cetilar line. The company was founded by Andrea Lacorte and Roberto Lacorte in 2003 and is headquartered in Pisa, Italy.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PHN is 53.9 EUR — it has increased by 0.37% in the past 24 hours. Watch PHARMANUTRA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange PHARMANUTRA stocks are traded under the ticker PHN.
PHN stock has fallen by −1.46% compared to the previous week, the month change is a −0.74% fall, over the last year PHARMANUTRA has showed a 10.22% increase.
We've gathered analysts' opinions on PHARMANUTRA future price: according to them, PHN price has a max estimate of 86.00 EUR and a min estimate of 76.00 EUR. Watch PHN chart and read a more detailed PHARMANUTRA stock forecast: see what analysts think of PHARMANUTRA and suggest that you do with its stocks.
PHN stock is 1.69% volatile and has beta coefficient of 0.60. Track PHARMANUTRA stock price on the chart and check out the list of the most volatile stocks — is PHARMANUTRA there?
Yes, you can track PHARMANUTRA financials in yearly and quarterly reports right on TradingView.
PHARMANUTRA is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
PHN earnings for the last quarter are 0.65 EUR per share, whereas the estimation was 0.60 EUR resulting in a 8.33% surprise. The estimated earnings for the next quarter are 0.43 EUR per share. See more details about PHARMANUTRA earnings.
PHARMANUTRA revenue for the last quarter amounts to 32.30 M EUR, despite the estimated figure of 32.50 M EUR. In the next quarter, revenue is expected to reach 25.30 M EUR.
PHN net income for the last quarter is 6.27 M EUR, while the quarter before that showed 2.63 M EUR of net income which accounts for 138.16% change. Track more PHARMANUTRA financial stats to get the full picture.
Yes, PHN dividends are paid annually. The last dividend per share was 0.85 EUR. As of today, Dividend Yield (TTM)% is 1.58%. Tracking PHARMANUTRA dividends might help you take more informed decisions.
PHARMANUTRA dividend yield was 1.51% in 2023, and payout ratio reached 64.04%. The year before the numbers were 1.28% and 51.42% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 10, 2024, the company has 105.00 employees. See our rating of the largest employees — is PHARMANUTRA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMANUTRA EBITDA is 24.27 M EUR, and current EBITDA margin is 24.80%. See more stats in PHARMANUTRA financial statements.
Like other stocks, PHN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMANUTRA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMANUTRA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMANUTRA stock shows the sell signal. See more of PHARMANUTRA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.